Maria Rinzivillo1, Ilaria De Felice1, Ludovica Magi1, Bruno Annibale2, Francesco Panzuto1. 1. Digestive Disease Unit, Sant' Andrea University Hospital, ENETS Center of Excellence, Rome, Italy. 2. Digestive Disease Unit, Sant' Andrea University Hospital, Department of Medical-Surgical Sciences and Translational Medicine, Sapienza University of Rome, ENETS Center of Excellence, Rome, Italy.
Abstract
BACKGROUND: In the last decades, the incidence of neuroendocrine neoplasia (NEN) increased from 1 to 5 new diagnoses/100,000 persons/year. The synthetic somatostatin analogues (SSAs) represent the first-choice treatment for both functionally active and inactive gastro-enteric-pancreatic NEN. This systematic review examines the role of octreotide long-acting release (LAR) in combination with other therapies for NEN management. METHODS: Primary outcomes were the disease control rate and the progression free survival (PFS), defined as the time between treatment initiation and progression of disease. Secondary outcomes were overall survival (OS) and safety. RESULTS: This systematic review identified 13 studies, concerning the use of octreotide LAR in association with other therapies in advanced NENs and included 1,206 patients. Patients were treated with octreotide LAR in combination with other drugs, mainly with everolimus (404 patients, 35%), but even with Peptide Receptor Radionuclide Therapy, bevacizumab, interferon or fluoride-derivatives. Disease control was observed in 85% cases with SSAs in combination with other therapies; PFS ranged from 15 to 16.4 months and OS from 25 to 61.9 months. SSAs are very well tolerated drugs, with few side effects which are usually mild, not requiring drug withdrawn. CONCLUSIONS: The review summarizes the effectiveness and available safety data on octreotide LAR in combination with other therapies in patients with NEN and may provide suggestions to address the therapeutic strategy. Further comparative head-to-head studies are needed to understand which is the best combination treatment for patients with progressive NEN after failure of first-line therapy. 2021 Journal of Gastrointestinal Oncology. All rights reserved.
BACKGROUND: In the last decades, the incidence of neuroendocrine neoplasia (NEN) increased from 1 to 5 new diagnoses/100,000 persons/year. The synthetic somatostatin analogues (SSAs) represent the first-choice treatment for both functionally active and inactive gastro-enteric-pancreatic NEN. This systematic review examines the role of octreotide long-acting release (LAR) in combination with other therapies for NEN management. METHODS: Primary outcomes were the disease control rate and the progression free survival (PFS), defined as the time between treatment initiation and progression of disease. Secondary outcomes were overall survival (OS) and safety. RESULTS: This systematic review identified 13 studies, concerning the use of octreotide LAR in association with other therapies in advanced NENs and included 1,206 patients. Patients were treated with octreotide LAR in combination with other drugs, mainly with everolimus (404 patients, 35%), but even with Peptide Receptor Radionuclide Therapy, bevacizumab, interferon or fluoride-derivatives. Disease control was observed in 85% cases with SSAs in combination with other therapies; PFS ranged from 15 to 16.4 months and OS from 25 to 61.9 months. SSAs are very well tolerated drugs, with few side effects which are usually mild, not requiring drug withdrawn. CONCLUSIONS: The review summarizes the effectiveness and available safety data on octreotide LAR in combination with other therapies in patients with NEN and may provide suggestions to address the therapeutic strategy. Further comparative head-to-head studies are needed to understand which is the best combination treatment for patients with progressive NEN after failure of first-line therapy. 2021 Journal of Gastrointestinal Oncology. All rights reserved.
Authors: K Oberg; L Kvols; M Caplin; G Delle Fave; W de Herder; G Rindi; P Ruszniewski; E A Woltering; B Wiedenmann Journal: Ann Oncol Date: 2004-06 Impact factor: 32.976
Authors: F Panzuto; M Di Fonzo; E Iannicelli; R Sciuto; C L Maini; G Capurso; M Milione; M S Cattaruzza; M Falconi; V David; V Ziparo; P Pederzoli; C Bordi; G Delle Fave Journal: Ann Oncol Date: 2005-12-19 Impact factor: 32.976
Authors: Jaume Capdevila; Alexandre Teulé; Jorge Barriuso; Daniel Castellano; Carlos Lopez; Jose Luis Manzano; Vicente Alonso; Rocío García-Carbonero; Emma Dotor; Ignacio Matos; Ana Custodio; Oriol Casanovas; Ramon Salazar Journal: Oncologist Date: 2018-05-23
Authors: Maria Rinzivillo; Ilaria De Felice; Ludovica Magi; Bruno Annibale; Francesco Panzuto Journal: Pancreatology Date: 2020-06-12 Impact factor: 3.996
Authors: James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans Journal: J Clin Oncol Date: 2008-06-20 Impact factor: 44.544
Authors: Johanna C Bendell; Ahmed Zakari; Evan Lang; David Waterhouse; Douglas Flora; Kathryn Alguire; Michael McCleod; Nancy Peacock; Peter Ruehlman; Cassie M Lane; Chris Earwood; Kent Shih Journal: Cancer Invest Date: 2016-04-29 Impact factor: 2.176
Authors: Arvind Dasari; Chan Shen; Daniel Halperin; Bo Zhao; Shouhao Zhou; Ying Xu; Tina Shih; James C Yao Journal: JAMA Oncol Date: 2017-10-01 Impact factor: 31.777
Authors: John K Ramage; A Ahmed; J Ardill; N Bax; D J Breen; M E Caplin; P Corrie; J Davar; A H Davies; V Lewington; T Meyer; J Newell-Price; G Poston; N Reed; A Rockall; W Steward; R V Thakker; C Toubanakis; J Valle; C Verbeke; A B Grossman Journal: Gut Date: 2011-11-03 Impact factor: 23.059